AlphAIAlphAI — Financial news for AI agents
massdevice.comSEP 302 min read$ABT

Abbott rolls out SimpleScreen colorectal cancer blood test developed by Freenome

Abbott (ABT) launched SimpleScreen CRC, a blood test for colorectal cancer screening, developed by Freenome and FDA-approved. It will be sold alongside Cologuard Plus, acquired via Exact Sciences. The test has 81.1% sensitivity for cancer. Medicare covers it for eligible patients. The ACS recommends blood tests only for those who decline preferred methods.

Original reporting
massdevice.com
Published Sep 30, 2026, 7:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 7:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Abbott rolls out SimpleScreen colorectal cancer blood test developed by Freenome — source image
Source · massdevice.com
Decision brief

The 30-second read

$ABTBullishMed
01

Why it matters

The new test diversifies Abbott's screening portfolio and could capture patients who decline stool or colonoscopy procedures.

02

Market read

Abbott's rollout may boost its diagnostics revenue and influence competitive dynamics in cancer screening.

03

What to watch

Reimbursement complexities and competition from Guardant Health's Shield test may limit upside.

Relevance 7/10Novelty 7/10Timing: immediate rollout

Background

Abbott recently acquired Exact Sciences, the maker of Cologuard, and is now adding a blood‑based test to its colorectal cancer screening suite.

Company-level read

Ticker impact

$ABTBullishHigh confidence
Context

Abbott announced the commercial rollout of the SimpleScreen CRC blood test, a new colorectal cancer screening product developed by Freenome.

Expected impact

modest upside as investors price in incremental sales from the new test

Evidence & confidence

First‑time commercial availability of a FDA‑cleared blood‑based cancer screen; Abbott's large distribution network should drive adoption.

Market effects

Sector

Strengthens the diagnostics and cancer‑screening segment, potentially pressuring peers.

Regional

U.S. healthcare market sees added screening option, may boost Medicare‑related diagnostics demand.

Global

Limited to U.S. market; minimal immediate global effect.

Counterpoint

What could challenge this read

Adoption could be slower than expected if physicians favor established stool‑based tests.

Key entities

  • Company
    Abbott Laboratories

    U.S. healthcare company launching the test.

  • Company
    Freenome

    Developer of the SimpleScreen CRC test.

Read at source← All news

Also covered by

3 outlets

Related articles

SEP 30
$ABTMedAI 8/10

Abbott Laboratories (ABT) Launches FDA-Approved SimpleScreen CRC

Abbott Laboratories (ABT) launched SimpleScreen CRC, an FDA-approved blood test for colorectal cancer screening. The test, developed with Freenome, detected 81.1% of cancers in trials. ABT offers a 2.51% dividend yield, a 7.7% 3-year growth rate, and is trading at $100.95, below its GF Value of $134.50. The company has a GF Score of 84, indicating strong financial health. Insiders have sold more shares than they bought in the past year.

gurufocus.com2 min
SEP 30
$ABTMedAI 8/10

Abbott (ABT) Launches FDA-Approved SimpleScreen CRC Test for Col

Abbott Laboratories (ABT) launched SimpleScreen CRC, an FDA-approved blood test for colorectal cancer screening. The company offers a 2.51% dividend yield, a GF Value of $134.50, and a GF Score of 84. Insiders have sold more shares than purchased recently, while guru investors show mixed activity. Abbott's diagnostics segment, including this new test, is part of its broader healthcare portfolio.

gurufocus.com2 min